1.Alzheimer’s Disease International. The global voivce on Dementia 2017 https://www.alz.co.uk/. Accessed 05 Janurary 2018.
2.Anand A, Khurana P, Chawla J, Sharma N, Khurana N. Emerging treatments for the behavioral and psychological symptoms of dementia. CNS Spectrums. 2017:1–9.
3.Kales HC, Gitlin LN, Lyketsos CG, Detroit Expert Panel A, Detroit Expert Panel on A, Management of Neuropsychiatric Symptoms of D, et al. Management of Neuropsychiatric Symptoms of Dementia in Clinical Settings: Recommendations from a Multidisciplinary Expert Panel. Journal of the American Geriatrics Society. 2014;62(4):762–9.
4.Sun M, Mainland BJ, Ornstein TJ, Mallya S, Fiocco AJ, Sin GL, et al. The association between cognitive fluctuations and activities of daily living and quality of life among institutionalized patients with dementia. International Journal of Geriatric Psychiatry. 2018;33(2):e280-e5.
5.Australian Institute of Health and Welfare. Dementia. 2016 https://www.aihw.gov.au/reports-data/health-conditions-disability-deaths/dementia/overview. Accessed 22 Feb 2018.
6.Antonsdottir IM, Makino KM, Porsteinsson AP. Dazed and Confused: Medical Cannabis in Alzheimer Disease. American Journal of Geriatric Psychiatry. 2016;24(11):1004–6.
7.Porsteinsson AP, Antonsdottir IM. An update on the advancements in the treatment of agitation in Alzheimer’s disease. Expert Opinion on Pharmacotherapy. 2017;18(6):611–20.
8.Maher AR, Maglione M, Bagley S, Suttorp M, Hu J-H, Ewing B, et al. Efficacy and Comparative Effectiveness of Atypical Antipsychotic Medications for Off-Label Uses in Adults: A Systematic Review and Meta-analysis. JAMA. 2011;306(12):1359–69.
9.Lin Y-T, Hwang T-J, Shan J-C, Chiang H-L, Sheu Y-H, Hwu H-G. Dosage and duration of antipsychotic treatment in demented outpatients with agitation or psychosis. Journal of the Formosan Medical Association. 2015;114(2):147–53.
10.McKeith I, Cummings J. Behavioural changes and psychological symptoms in dementia disorders. Lancet Neurology. 2005;4(11):735–42.
11.Foebel A, Ballokova A, Wellens NIH, Fialova D, Milisen K, Liperoti R, et al. A retrospective, longitudinal study of factors associated with new antipsychotic medication use among recently admitted long-term care residents. BMC Geriatrics. 2015;15(1):128.
12.Fakhoury M. Could cannabidiol be used as an alternative to antipsychotics? Journal of Psychiatric Research. 2016;80:14–21.
13.Woodward MR, Harper DG, Stolyar A, Forester BP, Ellison JM. Dronabinol for the Treatment of Agitation and Aggressive Behavior in Acutely Hospitalized Severely Demented Patients with Noncognitive Behavioral Symptoms. American Journal of Geriatric Psychiatry. 2014;22(4):415–9.
14.Ahmed AI, Elsen GAHvd, Colbers A, Kramers C, Burger DM, Marck MAvd, et al. Safety, pharmacodynamics, and pharmacokinetics of multiple oral doses of delta–9-tetrahydrocannabinol in older persons with dementia. Psychopharmacologia. 2015;232(14):2587–95.
15.Wilkinson ST, Radhakrishnan R, D’Souza DC. A Systematic Review of the Evidence for Medical Marijuana in Psychiatric Indications. Journal of Clinical Psychiatry. 2016;77(8):1050-.
16.Volicer L, Stelly M, Morris J, McLaughlin J, Volicer BJ. Effects of dronabinol on anorexia and disturbed behavior in patients with Alzheimer’s disease. International Journal of Geriatric Psychiatry. 1997;12(9):913–9.
17.Hausman-Kedem M, Kramer U. Efficacy of Medical Cannabis for Treating Refractory Epilepsy in Children and Adolescents, with Emphasis on the Israel Experience. Israel Medical Association Journal. 2017;19(2):76–8.
18.Krishnan S, Cairns R, Howard R. Cannabinoids for the treatment of dementia. Cochrane Database of Systematic Reviews. 2008(3).
19.Le Foll B, Tyndale RF. Cannabinoids: Friend or foe? Clinical Pharmacology & Therapeutics. 2015;97(6):528–31.
20.Bostwick JM. Blurred Boundaries: The Therapeutics and Politics of Medical Marijuana. Mayo Clinic Proceedings. 2012;87(2):172–86.
21.Cao CH, Li YQ, Liu H, Bai G, Mayl J, Lin XY, et al. The Potential Therapeutic Effects of THC on Alzheimer’s Disease. Journal of Alzheimers Disease. 2014;42(3):973–84.
22.Shelef A, Barak Y, Berger U, Paleacu D, Tadger S, Plopsky I, et al. Safety and Efficacy of Medical Cannabis Oil for Behavioral and Psychological Symptoms of Dementia: An-Open Label, Add-On, Pilot Study. Journal of Alzheimers Disease. 2016;51(1):15–9.
23.Khoury JM, Neves MdCLd, Roque MAV, Queiroz DAdB, Corrêa de Freitas AA, de Fátima Â, et al. Is there a role for cannabidiol in psychiatry? World Journal of Biological Psychiatry. 2017:1–16.
24.Turna J, Patterson B, Ameringen M. Is cannabis treatment for anxiety, mood, and related disorders ready for prime time? Depression and Anxiety. 2017;34(11):1006–17.
25.Aso E, Ferrer I. Cannabinoids for treatment of Alzheimer’s disease: moving toward the clinic. Frontiers in Pharmacology. 2014;5:37.
26.Nizynski B, Dzwolak W, Nieznanski K. Amyloidogenesis of Tau protein. Protein Science. 2017;26(11):2126–50.
27.Soto M, Andrieu S, Nourhashemi F, Ousset PJ, Ballard C, Robert P, et al. Medication development for agitation and aggression in Alzheimer disease: review and discussion of recent randomized clinical trial design. International Psychogeriatrics. 2015;27(2):181–97.
28.Walther S, Halpern M. Cannabinoids and dementia: A review of clinical and preclinical data. Pharmaceuticals. 2010;3(8):2689–708.
29.Eubanks LM, Rogers CJ, Beuscher Iv AE, Koob GF, Olson AJ, Dickerson TJ, et al. A molecular link between the active component of marijuana and Alzheimer’s disease pathology. Molecular Pharmaceutics. 2006;3(6):773–7.
30.Babalonis S, Haney M, Malcolm RJ, Lofwall MR, Votaw VR, Sparenborg S, et al. Oral cannabidiol does not produce a signal for abuse liability in frequent marijuana smokers. Drug and Alcohol Dependence. 2017;172:9–13.
31.De Souza Crippa JA, Zuardi AW, Garrido GEJ, Wichert-Ana L, Guarnieri R, Ferrari L, et al. Effects of Cannabidiol (CBD) on Regional Cerebral Blood Flow. Neuropsychopharmacology. 2004;29(2):417–26.
32.Chagas MHN, Zuardi AW, Tumas V, Pena-Pereira MA, Sobreira ET, Bergamaschi MM, et al. Effects of cannabidiol in the treatment of patients with Parkinson’s disease: An exploratory double-blind trial. Journal of Psychopharmacology. 2014;28(11):1088–92.
33.Finseth TA, Hedeman JL, Brown RP, Johnson KI, Binder MS, Kluger BM. Self-Reported Efficacy of Cannabis and Other Complementary Medicine Modalities by Parkinson’s Disease Patients in Colorado. Evidence-Based Complementary and Alternative Medicine. 2015;2015:874849.
34.Iffland K, Grotenhermen F. An Update on Safety and Side Effects of Cannabidiol: A Review of Clinical Data and Relevant Animal Studies. Cannabis and Cannabinoid Research. 2017;2(1):139–54.
35.Svendsen KB, Jensen TS, Bach FW. Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial. Biomeidcal Journal. 2004;329(7460):253–7.
36.Purcell C, Davis A, Moolman N, Taylor SM. Reduction of Benzodiazepine Use in Patients Prescribed Medical Cannabis. Cannabis and Cannabinoid Research. 2019.
37.Broers B, Patà Z, Mina A, Wampfler J, de Saussure C, Pautex S. Prescription of a THC/CBD-Based Medication to Patients with Dementia: A Pilot Study in Geneva. Medical Cannabis and Cannabinoids. 2019;2(1):56–9.
38. Walther S, Mahlberg R, Eichmann U, Kunz D. Delta–9-tetrahydrocannabinol for nighttime agitation in severe dementia. Psychopharmacology. 2006;185(4):524–8.
39.Passmore MJ. The cannabinoid receptor agonist nabilone for the treatment of dementia-related agitation. International Journal of Geriatric Psychiatry. 2008;23(1):116–7.
40.Amanullah S, MacDougall K, Sweeney N, Coffin J, Cole J. Synthetic cannabinoids in dementia with agitation: Case studies and literature review. Clinical Neuropsychiatry. 2013;10(3–4):142–7.
41.van den Elsen GAH, Tobben L, Ahmed AIA, Verkes RJ, Kramers C, Marijnissen RM, et al. Effects of tetrahydrocannabinol on balance and gait in patients with dementia: A randomised controlled crossover trial. Journal of Psychopharmacology. 2017;31(2):184–91.
42.van den Elsen GAH, Ahmed AIA, Verkes RJ, Kramers C, Feuth T, Rosenberg PB, et al. Tetrahydrocannabinol for neuropsychiatric symptoms in dementia A randomized controlled trial. Neurology. 2015;84(23):2338–46.
43.Sexton M, Cuttler C, Mischley LK. A Survey of Cannabis Acute Effects and Withdrawal Symptoms: Differential Responses Across User Types and Age. The Journal of Alternative and Complementary Medicine. 2019;25(3):326–35.
44.Folstein M. F., Folstein S. E., P.R: M. Mini-mental state: A practical method for grading the cognitive state of patients for the clinician. Journal Psychiatric Research. 1975;12:189–98.
45.Cummings JL. The Neuropsychiatric Inventory: Assessing psychopathology in dementia patients. Neurology. 1997;48(5):S10-S6.
46.Brett L, Traynor V, Stapley P, Meedya S.)Acceptability of the Cohen-Mansfield Agitation Inventory in an Australian residential aged care facility. Collegian. 2017; 24(6):579–84.
47.Logsdon RG, Gibbons LE, McCurry SM, Teri L. Assessing quality of life in older adults with cognitive impairment. Psychosomatic Medicine. 2002;64(3):510–9.
48.Edelman P, Fulton BR, Kuhn D, Chang C-H. A comparison of three methods of measuring dementia-specific quality of life: Perspectives of residents, staff, and observers. Gerontologist. 2005;45(1):27–36.
49.Abbey J, Piller N, Bellis AD, Esterman A, Parker D, Giles L, et al. The Abbey pain scale: a 1-minute numerical indicator for people with end-stage dementia. International Journal of Palliative Nursing. 2004;10(1):6–13.
50.Mehrotra DV. A recommended analysis for 2 x 2 crossover trials with baseline measurements. Pharmaceutical Statistics. 2014;13(6):376–87.
51.Wellek S, Blettner M. On the proper use of the crossover design in clinical trials: part 18 of a series on evaluation of scientific publications. Journal Article. 2012;109(15):276–81.
52.Mao HF, Kuo CA, Huang WN, Cummings JL, Hwang TJ. Values of the Minimal Clinically Important Difference for the Neuropsychiatric Inventory Questionnaire in Individuals with Dementia. Journal of the American Geriatrics Society. 2015;63(7):1448–52.
53.Walther S, Schüpbach B, Seifritz E, Homan P, Strik W. Randomized, controlled crossover trial of dronabinol, 2.5 mg, for agitation in 2 patients with dementia. Journal of Clinical Psychopharmacology. 2011;31(2):256–8.
54.American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders 5th ed. Arlington, VA: American Psychiatric Publishing; 2013.
55.Beattie E, O’Reilly M, Moyle W, Chenoweth L, Fetherstonhaugh D, Horner B, et al. Multiple perspectives on quality of life for residents with dementia in long term care facilities: protocol for a comprehensive Australian study. International Psychogeriatrics. 2015;27(10):1739–47.
56.Ettema TP, Dröes R-M, Lange Jd, Mellenbergh GJ, Ribbe MW. A Review of Quality of Life Instruments Used in Dementia. Quality of Life Research. 2005;14(3):675–86.
57.Gräske J, Verbeek H, Gellert P, Fischer T, Kuhlmey A, Wolf-Ostermann K. How to measure quality of life in shared-housing arrangements? A comparison of dementia-specific instruments. Quality of Life Research. 2014;23(2):549–59.
58.Weier M, Hall W. The Use of Cannabinoids in Treating Dementia. Current Neurology and Neuroscience Reports. 2017;17(8):1–9.
59.Lichtman AH, Lux EA, McQuade R, Rossetti S, Sanchez R, Sun W, et al. Results of a Double-Blind, Randomized, Placebo-Controlled Study of Nabiximols Oromucosal Spray as an Adjunctive Therapy in Advanced Cancer Patients with Chronic Uncontrolled Pain. Journal of Pain and Symptom Management. 2018;55(2):179–88.e1.
60.Queensland Health. Clinical Guidance: for the use of medicinal cannabis products in Queensland. 2017. p. 1–29 Accessed 20 November 2018.
61.Reese TR, Thiel DJ, Cocker KE. Behavioral Disorders in Dementia: Appropriate Nondrug Interventions and Antipsychotic Use. American Family Physician. 2016;94(4):276–82.
62.Feast A, Moniz-Cook E, Stoner C, Charlesworth G, Orrell M. A systematic review of the relationship between behavioral and psychological symptoms (BPSD) and caregiver well-being. International Psychogeriatrics. 2016;28(11):1761–74.Amanda